These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37554969)

  • 1. Alkylation of nucleobases by 2-chloro-
    Wie M; Khim KW; Groehler Iv AS; Heo S; Woo J; Son K; Lee EA; Ra JS; Hong SY; Schärer OD; Choi JH; Myung K
    NAR Cancer; 2023 Sep; 5(3):zcad042. PubMed ID: 37554969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
    Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    Oei AL; Ahire VR; van Leeuwen CM; Ten Cate R; Stalpers LJA; Crezee J; Kok HP; Franken NAP
    Int J Hyperthermia; 2018 Feb; 34(1):39-48. PubMed ID: 28540821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
    Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
    Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal recruitment of base excision DNA repair factors in living cells in response to different micro-irradiation DNA damage protocols.
    Zhao ML; Stefanick DF; Nadalutti CA; Beard WA; Wilson SH; Horton JK
    DNA Repair (Amst); 2023 Jun; 126():103486. PubMed ID: 37028218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
    Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
    Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
    Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
    Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
    Li P; Zhen Y; Kim C; Liu Z; Hao J; Deng H; Deng H; Zhou M; Wang XD; Qin T; Yu Y
    Sci Adv; 2023 Oct; 9(43):eadg7752. PubMed ID: 37878693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
    Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
    Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
    Wang LM; Wang P; Chen XM; Yang H; Song SS; Song Z; Jia L; Chen HD; Bao XB; Guo N; Huan XJ; Xi Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Lang JY; Miao ZH; Zhang A; He JX
    EMBO Mol Med; 2023 Mar; 15(3):e16235. PubMed ID: 36652375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
    Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
    Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.